12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lopinavir/ritonavir regulatory update

FDA granted tentative marketing approval to ANDAs from Cipla for lopinavir/ritonavir, from Hetero for abacavir and from Par's Par Formulations Private Ltd. subsidiary and from Micro Labs for efavirenz to treat HIV/AIDS infection. The products will be eligible for purchase outside the U.S. under the President's Emergency Plan...

Read the full 216 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >